New therapies in the form of specific antibodies and “small molecules” have ushered in a new era. Biologics intervene in the inflammatory process of atopic dermatitis by targeting individual cytokines. JAK inhibitors, on the other hand, are small-molecule agents that target inhibition of the JAK/STAT signaling pathway. In terms of personalized medicine, the focus is increasingly on selecting the most suitable drug for the individual.
Autoren
- Univ. Prof. Dr. med. Paul-Gunther Sator, M.Sc
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Lymphoma
Treatment goal: slow progression, improve quality of life
- PancNEN, PancNET & PancNEC
Neuroendocrine tumors of the pancreas
- Heart failure
Interventional treatment of the tricuspid valve
- Lipoprotein(a)
Current and future treatment options
- Lichen sclerosus
Topical corticosteroids still the first choice
- Breast Cancer
On the trail of triple-negative breast cancer
- Headache treatment
The therapy of migraine
- Sleep disorders in old age